Chemotherapy Effect Clinical Trial
Official title:
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Verified date | November 2019 |
Source | Medical University of Silesia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary goal:
Improvement of the therapeutic index by reducing the toxicity of treatment and increasing
local control of the cancer process while evaluating the possibility of conversion to the
surgical status.
Secondary targets:
- Survival rate (OS) assessment in patients treated with mFOLFIRINOX + SBRT
- Assessment of quality of life using questionnaires: EQ-5D, EORTC (QLQ-C30) and
pancreatic cancer-specific QLQ PAS module 26
- Early toxicity <3 months after completion of SBRT treatment.
- Percentage of local control (1-year)
Status | Completed |
Enrollment | 40 |
Est. completion date | July 31, 2019 |
Est. primary completion date | July 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Signing informed consent for treatment. 2. Age> = 18 years. 3. Patients with histopathological diagnosis of adenocarcinoma of the pancreas. 4. Advanced disease referred to as locally advanced definitive non-resetable, non-metastatic pancreatic cancer. 5. No prior systemic treatment due to pancreatic adenocarcinoma 6. No prior radiotherapy in the abdominal area 7. No prior radical surgical treatment due to pancreatic adenocarcinoma (palliative surgical procedures such as bypass surgery or biliary tract surgery are acceptable). 8. ECOG 0 or 1. 9. Expected survival time in excess of 12 weeks. 10. Adequate organ performance based on laboratory blood tests. Exclusion Criteria: 1. Patients diagnosed with other types of pancreatic cancer than adenocarcinomas (eg neuroendocrine cancer). 2. Advanced disease that allows primary surgical treatment. 3. Borderline pancreatic cancer (BRPC) disease. 4. The presence of metastases. 5. Previous systemic treatment because of pancreatic adenocarcinoma. 6. Preoperative radiotherapy in the abdominal area. 7. Previous radical surgery for pancreatic adenocarcinoma. 8. Large surgical procedure with the exception of diagnostic biopsies within the last 4 weeks after the start of treatment and / or patients who have not fully recovered after surgery. 9. Heart failure (NYHA Class II, III or IV) 10. Hemodynamic instability in the course of coronary and / or valvular heart disease and / or hypertension and / or other clinical conditions (eg uncontrolled diabetes mellitus). 11. Clinically relevant cardiac arrhythmias requiring treatment. 12. Stroke and / or myocardial infarction history within 6 months of inclusion. 13. Respiratory failure associated with other co-morbidities. 14. Serious psychiatric illnesses, which, in the researcher's opinion, could have a significant negative impact on the safety of the treatment. 15. Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment. 16. Transplanted organ transplant including allogeneic bone marrow transplant. 17. Positive diagnosis for HBV or HCV indicating acute or chronic infection (for screening). 18. HIV infection. 19. The period of pregnancy and breastfeeding. 20. Alcoholism or drug abuse. 21. Limited legal capacity. |
Country | Name | City | State |
---|---|---|---|
Poland | UCK Katowice | Katowice | Slaskie |
Lead Sponsor | Collaborator |
---|---|
Medical University of Silesia |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of the therapeutic index. | Improvement of the therapeutic index by reducing the toxicity of treatment and increasing local control of the cancer process while evaluating the possibility of conversion to the surgical status. | 24 months. | |
Primary | Improvement of the overall survival. | Improvement of the overall survival by new treatment method. | 60 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06376604 -
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
|
N/A | |
Completed |
NCT03753542 -
Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT04173195 -
Comfort Talk (CT) During Outpatient Chemotherapy
|
N/A | |
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Recruiting |
NCT03275194 -
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
|
Phase 2 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
Completed |
NCT04118322 -
The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT06043999 -
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Recruiting |
NCT05424692 -
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
|
N/A | |
Recruiting |
NCT04989985 -
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A |